查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511982

皮膚癌診斷市場規模、佔有率、趨勢分析報告：按癌症類型、測試類型、最終用途、地區和細分市場預測，2024-2030 年

Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Melanoma, Non-Melanoma), By Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

皮膚癌診斷市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球皮膚癌診斷市場規模將達到132.3億美元，2024年至2030年複合年成長率為5.52%。

皮膚癌診斷市場由幾個關鍵因素驅動。主要促進因素是由於紫外線照射增加和人口老化導致皮膚癌發生率增加。人工智慧成像和分子診斷等診斷技術的進步將提高準確性和早期檢測，進一步推動市場成長。提高認知宣傳活動和促進早期篩檢的政府舉措的增加也做出了重大貢獻。此外，增加醫療成本和改善皮膚科護理對於擴大皮膚癌診斷市場至關重要。

在過去的十年中，黑色素瘤檢測方法取得了重大進展，旨在減少黑色素瘤發病率和死亡率的增加。儘管有充分證據表明這些進步提高了黑色素瘤的早期檢測率，但對其提高存活率的有效性仍存在相當大的批評。檢測皮膚癌的傳統方法通常涉及耗時且昂貴的程序，例如 PET 掃描和電腦斷層掃描，以及使用射頻波的侵入性技術。

該生物感測器於 2024 年 4 月在倫敦大學瑪麗女王學院開發，提供了一種非侵入性且高效的解決方案。這種生物感測器利用太赫茲波的獨特特性來偵測細胞特性的細微變化，太赫茲波的能量比X光低，對人體更安全。此外，科學家們還開發了基因組測試，為腫瘤學家和皮膚科醫生提供有關腫瘤分子生物學的寶貴資訊，特別是為侵襲性黑色素瘤和高危險鱗狀細胞癌（SCC）患者提供。這些測試分析患者原發腫瘤的遺傳訊息，並幫助更好地預測癌症在治療後復發或擴散到身體其他部位的可能性。此外，這些測試提供了傳統癌症分期無法提供的針對患者的見解。傳統的癌症分期通常使用臨床資訊和實驗室報告與基於人群的資料進行比較來確定患者的預後。

在 COVID-19 時代，遠距皮膚科變得越來越流行。這些用於皮膚癌診斷的新興技術有可能整合到初級保健機構的遠距皮膚病學。此外，將人工智慧與這些新技術結合可以進一步加速它們的採用。需要更大規模的多中心前瞻性臨床試驗，以確保這些新技術不會僅作為少數專門中心使用的實驗設備。這可以透過維持每個國家的醫療保健提供者、一般民眾、患者和醫療保健組織對此問題的認知來實現。

皮膚癌診斷市場報告亮點

  • 由於非黑色素瘤皮膚癌（NMSC）盛行率的上升以及用於診斷非黑色素瘤的新型診斷工具的開發，預計非黑色素瘤將在預測期內成長。
  • 從測試類型來看，皮膚切片檢查占主導地位。皮膚切片檢查在皮膚癌診斷中極為重要，是明確診斷的黃金標準。市場促進因素包括患病率上升、切片檢查技術的進步以及病理分析的改進。提高認知和篩檢計劃正在鼓勵早期發現並推動對切片檢查的需求。
  • 診斷成像領域預計在此期間將以更快的速度成長。皮膚癌發生率上升、診斷影像方法（皮膚鏡檢查、光同調斷層掃瞄、共聚焦顯微鏡等）的技術進步以及早期檢測意識的提高等因素都有助於市場擴張。此外，擴大採用非侵入性成像技術來提高準確性並減少患者不適，這進一步推動了市場的成長。
  • 醫院和診所領域在最終用途領域佔據主導地位，預計在預測期內將以最快的速度成長。隨著診斷採用的增加，醫院也越來越接受它。醫院實驗室的發展對於滿足患者不斷變化的需求至關重要，越來越多的醫院致力於在其環境中提供廣泛的服務。
  • 由於主要企業的存在以及政府積極開發創新診斷工具等因素，北美在皮膚癌診斷市場佔據主導地位。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章皮膚癌診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 皮膚癌診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章皮膚癌診斷市場：按癌症類型的估計和趨勢分析

  • 全球皮膚癌診斷市場：按癌症類型分類的儀表板
  • 全球皮膚癌診斷市場：按癌症類型的波動分析
  • 全球皮膚癌診斷市場：按癌症類型和收益
  • 惡性黑色素瘤
  • 非黑色素瘤

第5章皮膚癌診斷市場：按測試類型估計和趨勢分析

  • 全球皮膚癌診斷市場：按測試類型分類的儀表板
  • 全球皮膚癌診斷市場：依測試類型進行差異分析
  • 全球皮膚癌診斷市場：按測試類型和收益
  • 皮膚鏡檢查
  • 皮膚切片檢查
  • 淋巴結活體組織切片
  • 影像檢查
  • 其他

第6章皮膚癌診斷市場：按測試類型估計和趨勢分析

  • 全球皮膚癌診斷市場：按最終用途分類的儀表板
  • 全球皮膚癌診斷市場：最終用途的變異分析
  • 全球皮膚癌診斷市場：依最終用途、按收益
  • 醫院和診所
  • 研究機構
  • 其他

第7章皮膚癌診斷市場：按癌症類型、測試類型和最終用途進行的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • Castle Bioscience
    • DermTech
    • bioMerieux , Inc.
    • FOUNDATION MEDICINE, INC.
    • DermaSensor, Inc.
    • F . Hoffmann-La Roche Ltd
    • NeoGenomics Laboratories
    • Quest Diagnostics Incorporated
    • SkylineDx
    • Abbott
Product Code: GVR-4-68040-322-6

Skin Cancer Diagnostics Market Growth & Trends:

The global skin cancer diagnostics market size is anticipated to reach USD 13.23 billion by 2030 and is expected to expand at a CAGR of 5.52% from 2024 to 2030, according to a new report by Grand View Research, Inc. The skin cancer diagnostics market is driven by several key factors. Rising skin cancer incidence due to increased UV exposure and aging populations is a primary driver. Advances in diagnostic technologies, such as AI-powered imaging and molecular diagnostics, enhance accuracy and early detection, further propelling market growth. Increased awareness campaigns and government initiatives promoting early screening also contribute significantly. In addition, higher healthcare expenditures and improved access to dermatological care are crucial in expanding the skin cancer diagnostics market.

Over the past decade, significant advancements have been made in approaches to melanoma detection, all aimed at reducing the growing incidence of melanoma and its mortality rate. While these advancements have been well-documented to increase early melanoma detection, there has been considerable criticism of their efficacy in improving survival rates. Traditional methods for detecting skin cancer often involve time-consuming and expensive procedures, such as PET and CT scans, as well as invasive technologies using higher frequencies.

A biosensor developed at Queen Mary University of London in April 2024 offers a noninvasive and highly efficient solution. This biosensor leverages the unique properties of THz waves, which have lower energy than X-rays and are safe for humans, to detect subtle changes in cell characteristics. In addition, scientists have developed genomic tests that provide oncologists and dermatologists with valuable information about the molecular biology of tumors, particularly in patients with aggressive skin cancers such as invasive melanomas and high-risk Squamous Cell Carcinomas (SCCs). These tests analyze genetic information from a patient's primary tumor, helping physicians better forecast the likelihood of cancer recurrence after treatment and its potential spread to other parts of the body. Furthermore, these tests offer greater patient-specific insights that are not available through traditional cancer staging, which typically uses clinical information and lab reports compared with population-based data to determine a patient's prognosis.

In the era of COVID-19, teledermatology has become increasingly popular. These emerging techniques for skin cancer diagnosis have the potential to be integrated into teledermatology in primary care settings. Furthermore, combining AI with these emerging techniques can further enhance their widespread use. More large-scale, multicenter, prospective clinical trials are needed to prevent these emerging techniques from remaining experimental equipment used in only a few special centers. This can be achieved by maintaining interest in this issue among health providers, the general population, patients, and health-related organizations in each country.

Skin Cancer Diagnostics Market Report Highlights:

  • Nonmelanoma dominated the cancer type segment and is anticipated to grow at fastest growth rate over the forecast period owing to the owing to the rising incidence of Nonmelanoma Skin Cancer (NMSC) and development of novel diagnostics tools for the diagnosis of no melanoma cancer
  • Skin biopsy dominated the test type segment. Skin biopsies are pivotal in skin cancer diagnostics, serving as the gold standard for definitive diagnosis. Market driving factors include the rising prevalence, advancements in biopsy techniques, and improved pathological analysis. Increased awareness and screening programs promote early detection, boosting biopsy demand
  • Imaging segment is expected to grow at faster rate during the review period. Factors such as the rising incidence of skin cancer, technological advancements in imaging modalities (like dermoscopy, optical coherence tomography, and reflectance confocal microscopy), and increasing awareness about early detection contribute to market expansion. Additionally, the growing adoption of non-invasive imaging techniques, which offer improved accuracy and reduced patient discomfort, further propel market growth
  • Hospitals and clinics segment dominated the end-use segment and is anticipated to grow at fastest growth rate over the forecast period. As diagnostics are being increasingly adopted, their acceptance has increased in hospitals as well. Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals are aiming to provide a wide range of services in their settings
  • North America dominated the skin cancer diagnostics market owing to factors such as the presence of major key players, favorable government initiatives for the development of innovative diagnostics tools

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer Type
    • 1.2.2. Test Type
    • 1.2.3. End-use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research End-use
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer Type and test type outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Skin Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements
      • 3.2.1.2. Integration of artificial intelligence
      • 3.2.1.3. Patient preference for non-invasive diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic Imaging
  • 3.3. Skin Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Skin Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis

  • 4.1. Global Skin Cancer Diagnostics Market: Cancer Type Dashboard
  • 4.2. Global Skin Cancer Diagnostics Market: Cancer Type Movement Analysis
  • 4.3. Global Skin Cancer Diagnostics Market by Cancer Type, Revenue
  • 4.4. Melanoma
    • 4.4.1. Melanoma market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Non-Melanoma
    • 4.5.1. Non-Melanoma market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Global Skin Cancer Diagnostics Market: Test Type Dashboard
  • 5.2. Global Skin Cancer Diagnostics Market: Test Type Movement Analysis
  • 5.3. Global Skin Cancer Diagnostics Market by Test Type, Revenue
  • 5.4. Dermatoscopy
    • 5.4.1. Dermatoscopy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Skin Biopsy
    • 5.5.1. Skin Biopsy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Lymph node biopsy
    • 5.6.1. Lymph node biopsy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Imaging Tests
    • 5.7.1. Imaging Tests market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 6.1. Global Skin Cancer Diagnostics Market: End-use Dashboard
  • 6.2. Global Skin Cancer Diagnostics Market: End-use Movement Analysis
  • 6.3. Global Skin Cancer Diagnostics Market by End-use, Revenue
  • 6.4. Hospital and Clinics
    • 6.4.1. Hospital and Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Laboratories
    • 6.5.1. Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Analysis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Skin Cancer Diagnostics Market: Regional Estimates & Trend Analysis by Cancer Type, Test Type and End-use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Castle Bioscience
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. DermTech
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. bioMerieux , Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. FOUNDATION MEDICINE, INC.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. DermaSensor, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. F . Hoffmann-La Roche Ltd
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. NeoGenomics Laboratories
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Quest Diagnostics Incorporated
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. SkylineDx
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Abbott
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 4 North America skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 5 North America skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 U.S. skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 7 U.S. skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 U.S. skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 10 Canada skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 11 Canada skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 14 Europe skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 15 Europe skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Germany skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 17 Germany skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 18 Germany skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 UK skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 20 UK skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 UK skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 23 France skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 24 France skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 26 Italy skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 27 Italy skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 29 Spain skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 30 Spain skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Denmark skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 32 Denmark skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 33 Denmark skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Sweden skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 35 Sweden skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 Sweden skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Norway skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 38 Norway skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 39 Norway skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 China skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 45 China skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 46 China skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Japan skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 48 Japan skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Japan skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 51 India skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 52 India skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 South Korea skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 54 South Korea skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 55 South Korea skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Australia skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 57 Australia skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Australia skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Thailand skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 60 Thailand skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 61 Thailand skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 64 Latin America skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 65 Latin America skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Brazil skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 67 Brazil skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 68 Brazil skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 70 Mexico skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 71 Mexico skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 73 Argentina skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 74 Argentina skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 MEA skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 77 MEA skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 78 MEA skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 South Africa skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 80 South Africa skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 81 South Africa skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 UAE skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 86 UAE skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 87 UAE skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Skin cancer diagnostics market: market outlook
  • Fig. 14 Skin cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Skin cancer diagnostics market driver impact
  • Fig. 18 Skin cancer diagnostics market restraint impact
  • Fig. 19 Skin cancer diagnostics market: Cancer Type movement analysis
  • Fig. 20 Skin cancer diagnostics market: Cancer Type outlook and key takeaways
  • Fig. 21 Melanoma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Non-Melanoma estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Skin cancer diagnostics market: Test Type movement analysis
  • Fig. 24 Skin cancer diagnostics market: Test Type outlook and key takeaways
  • Fig. 25 Dermatoscopy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Skin biopsy estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Lymph node biopsy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Imaging tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Skin cancer diagnostics market: End-use movement analysis
  • Fig. 31 Skin cancer diagnostics market: End-use outlook and key takeaways
  • Fig. 32 Hospital and clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Laboratories estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Global skin cancer diagnostics market: Regional movement analysis
  • Fig. 36 Global skin cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 37 Global skin cancer diagnostics market share and leading players
  • Fig. 38 North America, by country
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. key country dynamics
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Canada key country dynamics
  • Fig. 43 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK key country dynamics
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Japan key country dynamics
  • Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 India key country dynamics
  • Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand key country dynamics
  • Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea key country dynamics
  • Fig. 71 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Australia key country dynamics
  • Fig. 73 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Mexico key country dynamics
  • Fig. 78 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Argentina key country dynamics
  • Fig. 80 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 South Africa key country dynamics
  • Fig. 83 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Saudi Arabia key country dynamics
  • Fig. 85 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 UAE key country dynamics
  • Fig. 87 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Kuwait key country dynamics
  • Fig. 89 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Market share of key market players - Skin cancer diagnostics market